Whalegun
Lobbying

Alkeus Pharmaceuticals's latest lobbying report covers Q2 2026, at under $5,000. The four quarters Q3 2025–Q2 2026 total $130K. Its first report covers Q2 2024; the issues it reports most are Health Issues.

Alkeus Pharmaceuticals

Latest quarter
$0
Q2 2026 · 1 reports
Last 12 months
$130K
Last 4 quarters
vs last quarter
−100.0%
Q2 2026 against the quarter before
First report
Q2 2024
The first quarter a report named it

Lobbying by quarter

Alkeus Pharmaceuticals lobbying by quarter
Alkeus Pharmaceuticals lobbying by quarter
QuarterAmountReports
Q2 2024$60K1
Q3 2024$60K1
Q4 2024$60K1
Q1 2025$60K1
Q2 2025$60K1
Q3 2025$60K1
Q4 2025$60K1
Q1 2026$10K1
Q2 2026$01

Policy issues the reports name

  • Health issues7 reports

A report that names several issues counts once for each.

Who was lobbied

  • HOUSE OF REPRESENTATIVES7 reports
  • SENATE7 reports

Firms it paid

Firm
Akin Gump Strauss Hauer & Feld$430K9 quarters

Former officials lobbying for it

Former position
JOCELYN WILESStaffer, Rep. Kathy Castor (Jan. 07 - Feb. 11); Intern/Fellow, Rep. Barbara Lee (2006); Intern, Rep. Danny Davis (2004).Q4 2024
KANDIS MCCLUREIntern for Sen. Harry Reid, Jan. - Apr. 2013.Q3 2024
ED PAGANOAdvsr, Sen Harkin, 2014; Dep Asst to the President for Leg Affairs and Sen Liaison, Exec Ofc of the President, 2012-14; CoS, Sen Leahy, 2005-11; Sr Cnsl, Sen Judiciary Comm, 1997-04.Q2 2024

Lobbying reports

Filed by
07/20for Q2Akin Gump Strauss Hauer & FeldUnder $5,000
04/20for Q1Akin Gump Strauss Hauer & Feld$10K
01/20for Q4 2025Akin Gump Strauss Hauer & Feld$60K
25/10/20for Q3 2025Akin Gump Strauss Hauer & Feld$60K
25/07/21for Q2 2025Akin Gump Strauss Hauer & Feld$60K
25/04/21for Q1 2025Akin Gump Strauss Hauer & Feld$60K
25/01/21for Q4 2024Akin Gump Strauss Hauer & Feld$60K
24/10/18for Q3 2024Akin Gump Strauss Hauer & Feld$60K
24/07/19for Q2 2024Akin Gump Strauss Hauer & Feld$60K
24/04/26for Q2 2024Akin Gump Strauss Hauer & FeldUnder $5,000